Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 1.23 is 25% above its 5-year average of 0.98, around the middle of its 5-year range (0.01–2.41).
As of the fiscal period ended Tuesday, June 30, 2026. 25.31% above its 12-month average of 0.98.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.23.
QUICK RATIO (ACID-TEST)
1.23
QUICK RATIO (ACID-TEST) AVG TTM
0.98
QUICK RATIO (ACID-TEST) AVG 3Y
0.78
QUICK RATIO (ACID-TEST) AVG 5Y
0.98
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+25.31%
CURRENT VS 3Y AVG
+56.89%
CURRENT VS 5Y AVG
+25.24%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
-63.33%
vs the sector median at left
MiNK Therapeutics, Inc.
Market Cap
$58.29M
Quick Ratio (Acid-Test)
1.23
TTM Avg
0.98
3Y Avg
0.78
5Y Avg
0.98
Market Cap
$58.43M
Quick Ratio (Acid-Test)
6.71
TTM Avg
8.38
3Y Avg
9.61
5Y Avg
10.03
Market Cap
$58.44M
Quick Ratio (Acid-Test)
0.57
TTM Avg
2.81
3Y Avg
4.44
5Y Avg
7.47
Market Cap
$58.06M
Quick Ratio (Acid-Test)
10.98
TTM Avg
17.43
3Y Avg
9.10
5Y Avg
12.08
Market Cap
$57.76M
Quick Ratio (Acid-Test)
9.48
TTM Avg
13.86
3Y Avg
12.45
5Y Avg
13.81
Market Cap
$57.61M
Quick Ratio (Acid-Test)
4.29
TTM Avg
4.53
3Y Avg
3.33
5Y Avg
3.09
Market Cap
$59.18M
Quick Ratio (Acid-Test)
4.25
TTM Avg
2.40
3Y Avg
3.43
5Y Avg
5.08
Market Cap
$57.01M
Quick Ratio (Acid-Test)
2.37
TTM Avg
7.60
3Y Avg
7.51
5Y Avg
12.19
Market Cap
$60.02M
Quick Ratio (Acid-Test)
1.35
TTM Avg
1.97
3Y Avg
5.50
5Y Avg
8.52
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | $58.29M | 1.23 | 0.98 | 0.78 | 0.98 |
| Adicet Bio, Inc. (ACET)vs › | $58.43M | 6.71 | 8.38 | 9.61 | 10.03 |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | 0.57 | 2.81 | 4.44 | 7.47 |
| Kalaris Therapeutics Inc (KLRS)vs › | $58.06M | 10.98 | 17.43 | 9.10 | 12.08 |
| Boundless Bio, Inc. (BOLD)vs › | $57.76M | 9.48 | 13.86 | 12.45 | 13.81 |
| Talphera, Inc. (TLPH)vs › | $57.61M | 4.29 | 4.53 | 3.33 | 3.09 |
| Xilio Therapeutics, Inc. (XLO)vs › | $59.18M | 4.25 | 2.40 | 3.43 | 5.08 |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.01M | 2.37 | 7.60 | 7.51 | 12.19 |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.02M | 1.35 | 1.97 | 5.50 | 8.52 |
| Fractyl Health, Inc. (GUTS)vs › | $60.42M | 3.15 | 4.21 | 4.66 | 4.26 |
Quick Ratio
1.23
Excludes inventory
Current Ratio
1.23
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 1.23 |
| 2026-03-31 | 1.38 |
| 2025-12-31 | 1.06 |
| 2025-09-30 | 1.08 |
| 2025-06-30 | 0.15 |
| 2025-03-31 | 0.30 |
| 2024-12-31 | 0.72 |
| 2024-09-30 | 0.89 |
| 2024-06-30 | 0.93 |
| 2024-03-31 | 0.54 |
| 2023-12-31 | 0.32 |
| 2023-09-30 | 0.62 |
| 2023-06-30 | 0.96 |
| 2023-03-31 | 1.38 |
| 2022-12-31 | 1.61 |
| 2022-09-30 | 1.33 |
| 2022-06-30 | 1.74 |
| 2022-03-31 | 1.88 |
| 2021-12-31 | 2.41 |
| 2021-09-30 | 0.01 |
| 2021-06-30 | 0.06 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | 0.29 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
